Abstract
AbstractInterleukin 32 (IL32) is a pro-inflammatory cytokine that plays a key role in promoting sterile inflammation by modulating immune responses. However, the role of IL32 in various cancers remains unclear. This research aimed to investigate the correlation between IL32 expression and immunity and visualize its prognostic landscape in pan-cancer. We investigated gene expression, genomic alterations, and survival analysis of IL32 in pan-cancer in numerous databases including TCGA, GTEx, cBioPortal, and GDC databases. Tumor immune cell infiltration was assessed using the CIBERSORT computational method as well as the ESTIMATE method to analyze the correlation of IL32 expression with stromal and immune components. Protein–protein interaction analysis was performed in the STRING and GeneMANIA databases, and gene function enrichment was performed by GO set enrichment analysis. Tumor tissues had higher IL32 expression levels than normal tissues. Elevated IL32 expression was associated with poor OS and prognosis. In addition, tumor stemness, TMB, MSI, and immune checkpoint genes were also associated with IL32 expression. Correlations were observed between IL32 expression and B cell, CD4T cell, CD8T cell, neutrophil, macrophage, and DC infiltration in multiple cancers. GO enrichment analysis showed that IL32 expression was associated with cancer pathways, cytokine-receptor interactions, and NOD-like receptor signaling pathways. These findings suggest that IL32 may serve as a biomarker of cancer immune infiltration and poor prognosis, providing new therapeutic targets for cancer treatment.
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Dahl, C. A. et al. Identification of a novel gene expressed in activated natural killer cells and T cells. J. Immunol. 148(2), 597–603 (1992).
2. Kim, S. H. et al. Interleukin-32: A cy-tokine and inducer of TNFalpha. Immunity 22(1), 131–142 (2005).
3. Zeng, Q. et al. Interleukin-32 contributes to invasion and metastasis of primary lung adenocarcino-ma via NF -kappaB induced matrix metalloproteinases 2 and 9 expression. Cytokine 65(1), 24–32 (2014).
4. Khawar, M. B. et al. IL-32θ: A recently identified anti-inflammatory variant of IL-32 and its preventive role in various disorders and tumor suppressor activity. Am. J. Transl. Res. 9(11), 4726–4737 (2017).
5. Srivastava, S. & Hanash, S. Pan-cancer early detection: Hype or hope?. Cancer Cell 38(1), 23–24 (2020).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献